AxoGen

AxoGen is a developer of surgical solutions, including human tissue grafts, based in Alachua, Florida.[1] Axogen products are designed to remedy peripheral nerve damage.[2][3] In 2013 the company raised $18 million in its Initial Public Offering (IPO).[4] AxoGen uses a cell graft technology AVANCE to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes.[5] The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. AxoGen is part of the Sid Martin Biotechnology Incubator.

AxoGen
Traded asNASDAQ: AXGN
Russell 2000 Component
Industrybiotechnology 
Headquarters
Alachua 
,
United States of America 
Websitewww.axogeninc.com/ 

As of 2019, AxoGen was the only commercially available allograft approved by the Food and Drug Administration (FDA) for clinical use.[6]

See also

References
  1. Inc, Axogen (2020-05-06). "Axogen, Inc. Reports First Quarter 2020 Financial Results". GlobeNewswire News Room. Retrieved 2020-06-03.
  2. Graft Helps Nerves Regrow; More Patients Avoid Amputation Through Technique Based on Cadaver Implant December 26, 2012 by Melinda Beck
  3. Nerve repair using grafts from cadavers; SURGERY Grafts from cadavers offer alternative, providing more choice, less traumaby Drew Joseph February 19, 2013 San Francisco Chronicle (SFGate)
  4. [Alachua] Business Briefs November 2013 Florida Trend Magazine
  5. "Bloomberg - Are you a robot?". www.bloomberg.com. Retrieved 2020-06-03.
  6. "Nerve Allograft - an overview | ScienceDirect Topics". www.sciencedirect.com. Retrieved 2020-06-03.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.